Spots Global Cancer Trial Database for phase 2
Every month we try and update this database with for phase 2 cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| A Study to Evaluate the Efficacy and Safety of Simtuzumab Combined With Gemcitabine for Metastatic Pancreatic Adenocarcinoma | NCT01472198 | Pancreatic Canc... | Simtuzumab Gemcitabine Placebo to matc... | 18 Years - | Gilead Sciences | |
| Study of NUV-422 in Combination With Fulvestrant in Patients With HR+HER2- aBC | NCT05191004 | Advanced Breast... Metastatic Brea... Breast Cancer Breast Carcinom... Cancer of the B... Cancer of Breas... Malignant Tumor... Breast Tumor | NUV-422 Fulvestrant | 18 Years - | Nuvation Bio Inc. | |
| Anti-Tumor Activity Of SB-485232 In Patients With Previously Untreated Metastatic Melanoma | NCT00107718 | Melanoma | SB-485232 | 18 Years - | GlaxoSmithKline | |
| Safety and Efficacy of CC-486 in Previously Treated Patients With Locally Advanced or Metastatic Nasopharyngeal Carcinoma | NCT02269943 | Nasopharyngeal ... | CC-486 | 18 Years - | Celgene | |
| Ofatumumab In Older Patients With Untreated Low Or Intermediate Risk Indolent B-Cell Lymphomas | NCT01263418 | Lymphoma, Non-H... Lymphoma, Folli... Lymphoma, B-Cel... Lymphoma, Low-G... Lymphoma, Inter... | Ofatumumab | 70 Years - | UNC Lineberger Comprehensive Cancer Center | |
| Lenvatinib, Pembrolizumab, and Paclitaxel for Treatment of Recurrent Endometrial, Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer | NCT04781088 | Platinum-Resist... Platinum-Resist... Platinum-Resist... Recurrent Endom... Recurrent Fallo... Recurrent Ovari... Recurrent Prima... | Lenvatinib Paclitaxel Pembrolizumab | 18 Years - | Ohio State University Comprehensive Cancer Center | |
| Anti-Tumor Activity Of SB-485232 In Patients With Previously Untreated Metastatic Melanoma | NCT00107718 | Melanoma | SB-485232 | 18 Years - | GlaxoSmithKline | |
| A Study of Carboplatin, Pemetrexed Plus Placebo vs Carboplatin, Pemetrexed Plus 1 or 2 Truncated Courses of Demcizumab in Subjects With Non-Squamous Non-Small Cell Lung Cancer | NCT02259582 | Nonsquamous Non... | Pemetrexed Carboplatin demcizumab | 21 Years - | Mereo BioPharma | |
| Dose Escalation, Expansion Study of Vofatamab (B-701) in Treatment of Locally Advanced or Metastatic Urothelial Cell Carcinoma | NCT02401542 | Locally Advance... Urinary Bladder... Urological Dise... | Vofatamab Docetaxel Placebo | 18 Years - | Rainier Therapeutics | |
| Alisertib in Chemotherapy-pretreated Urothelial Cancer | NCT02109328 | Bladder Cancer Transitional Ce... | Alisertib Paclitaxel Placebo | 18 Years - | Fondazione IRCCS Istituto Nazionale dei Tumori, Milano | |
| RX-5902 Treatment of Subjects With Triple Negative Breast Cancer | NCT02003092 | Solid Tumor Triple Negative... | RX-5902 | 18 Years - | Rexahn Pharmaceuticals, Inc. | |
| A Study of JNJ-40346527 in Patients With Relapsed or Refractory Hodgkin Lymphoma | NCT01572519 | Relapsed or Ref... | Phase 1, Cohort... Phase 1, Cohort... Phase 1, Cohort... Phase 1, Cohort... Phase 2 | 18 Years - | Janssen Research & Development, LLC | |
| A Trial of Lenvatinib (E7080) in Subjects With Iodine-131 Refractory Differentiated Thyroid Cancer to Evaluate Whether an Oral Starting Dose of 18 Milligram (mg) Daily Will Provide Comparable Efficacy to a 24 mg Starting Dose, But Have a Better Safety Profile | NCT02702388 | Thyroid Cancer | Lenvatinib Lenvatinib matc... | 18 Years - | Eisai Inc. | |
| Study of Ipilimumab, Nivolumab, and Cabozantinib in Patients With Cutaneous Melanoma | NCT05200143 | Refractory Cuta... | Ipilimumab Nivolumab Cabozantinib | 18 Years - | Providence Health & Services | |
| Study of NUV-422 in Combination With Enzalutamide in Patients With mCRPC | NCT05191017 | Prostate Cancer Prostatic Cance... Cancer of Prost... Cancer of the P... Prostate Neopla... Castrate Resist... Castration Resi... Castration Resi... | NUV-422 Enzalutamide | 18 Years - | Nuvation Bio Inc. | |
| A Study to Test the Efficacy, Safety, and Pharmacokinetics of Rozanolixizumab in Adult Study Participants With Leucine-Rich Glioma Inactivated 1 Autoimmune Encephalitis | NCT04875975 | Leucine-Rich Gl... | Rozanolixizumab Placebo | 18 Years - 89 Years | UCB Pharma | |
| Lenvatinib Plus Pembrolizumab In Patients With Immune Checkpoint Inhibitor Naïve Metastatic Uveal Melanoma | NCT05308901 | Melanoma, Uveal | Pembrolizumab Lenvatinib | 18 Years - | Providence Health & Services | |
| Study of E7777 in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma and Cutaneous T-cell Lymphoma | NCT02676778 | Peripheral T-ce... Cutaneous T-cel... | E7777 | 20 Years - | Eisai Inc. | |
| Erlotinib Versus Oral Etoposide in Patients With Recurrent or Refractory Pediatric Ependymoma | NCT01032070 | Recurrent or Re... | erlotinib etoposide | 1 Year - 21 Years | Astellas Pharma Inc | |
| A Study of MBG453 in Combination With Azacitidine and Venetoclax in AML Patients Unfit for Chemotherapy | NCT04150029 | Acute Myeloid L... | MBG453 Venetoclax Azacitidine | 18 Years - | Novartis | |
| A Study of Recombinant Vaccinia Virus to Treat Unresectable Primary Hepatocellular Carcinoma | NCT00554372 | Carcinoma, Hepa... | JX-594: Recombi... | 18 Years - | SillaJen, Inc. | |
| Study Evaluating HKI-272 (Neratinib) In Subjects With Advanced Breast Cancer | NCT00300781 | Breast Neoplasm... Neoplasms | neratinib | 18 Years - | Puma Biotechnology, Inc. | |
| Neoadjuvant Immunoradiotherapy in Head & Neck Cancer (NIRT 2-HNC) | NCT04938609 | Head and Neck C... Head and Neck S... | Pembrolizumab Stereotactic Bo... Surgical Resect... | 18 Years - | Providence Health & Services | |
| A Trial to Evaluate Multiple Regimens in Newly Diagnosed and Recurrent Glioblastoma | NCT03970447 | Glioblastoma | Temozolomide Lomustine Regorafenib Radiation Paxalisib VAL-083 VT1021 Troriluzole ADI-PEG 20 | 18 Years - | Global Coalition for Adaptive Research | |
| Deciphering Afatinib Response and Resistance With INtratumour Heterogeneity | NCT02183883 | Non-small Cell ... | Afatinib | 18 Years - | University College, London | |
| Very Early PET-response Adapted Targeted Therapy for Advanced Hodgkin Lymphoma: a Single -Arm Phase II Study | NCT03517137 | Advanced Hodgki... | Brentuximab Ved... Adriamycin Vinblastine Dacarbazine Etoposide Cyclophosphamid... Radiation Thera... | 18 Years - 60 Years | European Organisation for Research and Treatment of Cancer - EORTC | |
| Study Evaluating HKI-272 (Neratinib) In Subjects With Advanced Breast Cancer | NCT00300781 | Breast Neoplasm... Neoplasms | neratinib | 18 Years - | Puma Biotechnology, Inc. | |
| A Study to Determine the Safety and Efficacy for the Combination of Durvalumab and Daratumumab in Relapsed and Refractory Multiple Myeloma | NCT02807454 | Multiple Myelom... | Daratumumab Durvalumab Pomalidomide Dexamethasone | 18 Years - | Celgene | |
| Lenvatinib Plus Pembrolizumab In Patients With Immune Checkpoint Inhibitor Naïve Metastatic Uveal Melanoma | NCT05308901 | Melanoma, Uveal | Pembrolizumab Lenvatinib | 18 Years - | Providence Health & Services | |
| Efficacy and Safety of OncoGel™ Added to Chemotherapy and Radiation Before Surgery in Subjects With Esophageal Cancer | NCT00573131 | Esophageal Canc... Adenocarcinoma ... Squamous Cell C... | OncoGel (Paclit... cisplatin 5-FU radiation thera... esophageal rese... | 18 Years - | Boston Scientific Corporation | |
| An Efficacy and Safety Study of bb2121 in Subjects With Relapsed and Refractory Multiple Myeloma and in Subjects With High-Risk Multiple Myeloma | NCT03601078 | Multiple Myelom... | bb2121 Lenalomide Talquetamab | 18 Years - | Celgene | |
| Lenvatinib Plus Pembrolizumab In Patients With Immune Checkpoint Inhibitor Naïve Metastatic Uveal Melanoma | NCT05308901 | Melanoma, Uveal | Pembrolizumab Lenvatinib | 18 Years - | Providence Health & Services | |
| Encorafenib and Binimetinib With or Without Nivolumab in Treating Patients With Metastatic Radioiodine Refractory BRAF V600 Mutant Thyroid Cancer | NCT04061980 | BRAF NP_004324.... BRAF V600E Muta... Metastatic Thyr... Refractory Thyr... Stage IV Differ... Stage IVA Diffe... Stage IVB Diffe... | Binimetinib Encorafenib Nivolumab | 18 Years - | Providence Health & Services | |
| Investigating the Effects of Atezolizumab in People Whose Tumour DNA or RNA Indicates Possible Sensitivity | NCT04273061 | Breast Cancer Lung Cancer Gastrointestina... Genitourinary C... Gynecologic Can... Sarcoma Unknown Primary... Head and Neck C... Skin Cancer | Atezolizumab | 18 Years - | British Columbia Cancer Agency | |
| A Study of Recombinant Vaccinia Virus to Treat Unresectable Primary Hepatocellular Carcinoma | NCT00554372 | Carcinoma, Hepa... | JX-594: Recombi... | 18 Years - | SillaJen, Inc. | |
| Safety and Efficacy of CC-486 in Previously Treated Patients With Locally Advanced or Metastatic Nasopharyngeal Carcinoma | NCT02269943 | Nasopharyngeal ... | CC-486 | 18 Years - | Celgene | |
| Bendamustine + Rituximab in Older Patients With Previously Untreated Diffuse Large B-cell Lymphoma | NCT01234467 | Diffuse Large B... Lymphoma, Diffu... Diffuse Large-C... Lymphoma | Bendamustine Rituximab | 65 Years - | UNC Lineberger Comprehensive Cancer Center | |
| Pegylated Liposomal Doxorubicine and Prolonged Temozolomide in Addition to Radiotherapy in Newly Diagnosed Glioblastoma | NCT00944801 | Glioblastoma | Pegylated Lipos... | 18 Years - 70 Years | University of Regensburg | |
| Improving Tumor Treating Fields Treatment for Brain Cancer Patients With Skullremodeling Surgery (Neurosurgery) | NCT04223999 | Recurrent Gliob... | Skullremodeling... Control | 18 Years - | University of Aarhus | |
| NGS as the First-line Treatment in Advanced Biliary Tract Cancer | NCT04172402 | Advanced Biliar... | TS-1 Gemcitabine Nivolumab | 20 Years - | National Health Research Institutes, Taiwan | |
| RX-5902 Treatment of Subjects With Triple Negative Breast Cancer | NCT02003092 | Solid Tumor Triple Negative... | RX-5902 | 18 Years - | Rexahn Pharmaceuticals, Inc. | |
| Japanese Phase 2 Study to Evaluate the Efficacy and Safety of Pomalidomide in Subjects With Relapsed and Refractory Multiple Myeloma | NCT02011113 | Multiple Myelom... | Pomalidomide Dexamethasone | 20 Years - | Celgene Corporation | |
| Study of NUV-422 in Combination With Enzalutamide in Patients With mCRPC | NCT05191017 | Prostate Cancer Prostatic Cance... Cancer of Prost... Cancer of the P... Prostate Neopla... Castrate Resist... Castration Resi... Castration Resi... | NUV-422 Enzalutamide | 18 Years - | Nuvation Bio Inc. | |
| Encorafenib and Binimetinib With or Without Nivolumab in Treating Patients With Metastatic Radioiodine Refractory BRAF V600 Mutant Thyroid Cancer | NCT04061980 | BRAF NP_004324.... BRAF V600E Muta... Metastatic Thyr... Refractory Thyr... Stage IV Differ... Stage IVA Diffe... Stage IVB Diffe... | Binimetinib Encorafenib Nivolumab | 18 Years - | Providence Health & Services | |
| A Study of 131I-TM601 in Adults With Recurrent Malignant Glioma | NCT00683761 | Malignant Gliom... Glioblastoma Mu... GBM Astrocytoma Oligodendroglio... | 131I-TM601 | 18 Years - | TransMolecular | |
| Study of Sotatercept for the Treatment of Anemia in low-or Intermediate-1 Risk Myelodysplastic Syndromes (MDS) or Non-proliferative Chronic Myelomonocytic Leukemia (CMML) | NCT01736683 | Anemia Myelodysplastic... Chronic Myelomo... Low to Intermed... Myelodysplastic... Chronic Myelomo... | Sotatercept | 18 Years - | Merck Sharp & Dohme LLC | |
| Evaluation of IPI-549 Combined With Front-line Treatments in Pts. With Triple-Negative Breast Cancer or Renal Cell Carcinoma | NCT03961698 | Breast Cancer Renal Cell Carc... | IPI-549 (eganel... Atezolizumab nab-paclitaxel Bevacizumab | 18 Years - | Infinity Pharmaceuticals, Inc. | |
| Study of NY-ESO-1 ISCOMATRIX® in Patients With Measurable Stage III or IV Melanoma | NCT00518206 | Melanoma | NY-ESO-1 ISCOMA... Cyclophosphamid... | 18 Years - | Ludwig Institute for Cancer Research | |
| A Phase 1/2 Trial of SRA737 in Subjects With Advanced Cancer | NCT02797964 | Advanced Solid ... | SRA737 | 18 Years - | Sierra Oncology LLC - a GSK company | |
| First-Line Gemcitabine Chemotherapy With Our Without Sunitinib In Advanced or Metastatic Pancreatic Cancer | NCT00673504 | Pancreatic Canc... | Gemcitabine + S... Gemcitabine | 18 Years - | Central European Society for Anticancer Drug Research | |
| Pegylated Liposomal Doxorubicine and Prolonged Temozolomide in Addition to Radiotherapy in Newly Diagnosed Glioblastoma | NCT00944801 | Glioblastoma | Pegylated Lipos... | 18 Years - 70 Years | University of Regensburg | |
| A Safety and Efficacy Study of Intravenous 131I-TM601 in Adult Patients With Malignant Melanoma | NCT00733798 | Melanoma Malignant Melan... Metastatic Mela... | 131I-TM601 | 18 Years - | TransMolecular | |
| Study Tests The Safety And Effectiveness Of SU011248 In Patients With Non-Small Cell Lung Cancer Having Brain Metastases | NCT00372775 | Non-Small Cell ... | Sunitinib | 18 Years - | Pfizer | |
| Bendamustine + Rituximab in Older Patients With Previously Untreated Diffuse Large B-cell Lymphoma | NCT01234467 | Diffuse Large B... Lymphoma, Diffu... Diffuse Large-C... Lymphoma | Bendamustine Rituximab | 65 Years - | UNC Lineberger Comprehensive Cancer Center | |
| Study of NUV-422 in Combination With Fulvestrant in Patients With HR+HER2- aBC | NCT05191004 | Advanced Breast... Metastatic Brea... Breast Cancer Breast Carcinom... Cancer of the B... Cancer of Breas... Malignant Tumor... Breast Tumor | NUV-422 Fulvestrant | 18 Years - | Nuvation Bio Inc. | |
| An Open-label Study of Encorafenib + Binimetinib in Patients With BRAFV600-mutant Non-small Cell Lung Cancer | NCT03915951 | Non-small Cell ... | encorafenib binimetinib | 18 Years - | Pfizer | |
| Nimotuzumab Plus Radiotherapy With Concomitant and Adjuvant Temozolomide for Cerebral Glioblastoma | NCT03388372 | Glioblastoma | Nimotuzumab Temozolomide Radiotherapy | 18 Years - 75 Years | Biotech Pharmaceutical Co., Ltd. | |
| Trastuzumab in Combination With Capecitabine and Oxaliplatin(XELOX) in Patients With Advanced Gastric Cancer(AGC): Her+XELOX | NCT01396707 | Metastatic or R... Her-2 Positive ... | Herceptin+XELOX | 20 Years - | Asan Medical Center | |
| Bendamustine + Rituximab in Older Patients With Previously Untreated Diffuse Large B-cell Lymphoma | NCT01234467 | Diffuse Large B... Lymphoma, Diffu... Diffuse Large-C... Lymphoma | Bendamustine Rituximab | 65 Years - | UNC Lineberger Comprehensive Cancer Center | |
| A Safety and Efficacy Study of Intravenous 131I-TM601 in Adult Patients With Malignant Melanoma | NCT00733798 | Melanoma Malignant Melan... Metastatic Mela... | 131I-TM601 | 18 Years - | TransMolecular | |
| Study of SRF617 With AB928 (Etrumadenant) and AB122 (Zimberelimab) in Patients With Metastatic Castration Resistant Prostate Cancer | NCT05177770 | Metastatic Cast... Prostate Cancer | SRF617 etrumadenant zimberelimab | 18 Years - | Coherus Biosciences, Inc. | |
| A Study With Pembrolizumab in Combination With Dual Anti-HER2 Blockade With Trastuzumab and Pertuzumab in Early Breast Cancer Patients With Molecular HER2-enriched Intrinsic Subtype (Keyriched-1) | NCT03988036 | Breast Cancer | Pembrolizumab Trastuzumab Bio... Pertuzumab | 18 Years - | West German Study Group | |
| Trial of Atezolizumab and Bevacizumab With SRF388 or Placebo in Patients With Hepatocellular Carcinoma | NCT05359861 | Hepatocellular ... | SRF388 Atezolizumab Bevacizumab Placebo | 18 Years - | Coherus Biosciences, Inc. | |
| Alisertib in Chemotherapy-pretreated Urothelial Cancer | NCT02109328 | Bladder Cancer Transitional Ce... | Alisertib Paclitaxel Placebo | 18 Years - | Fondazione IRCCS Istituto Nazionale dei Tumori, Milano | |
| Pyronaridine in Acute Lymphoblastic Leukemia (ALL) and Acute Myeloid Leukemia (AML) | NCT05291390 | Acute Myeloid L... Acute Lymphobla... | Pyronaridine Te... | 18 Years - | Armaceutica, Inc. | |
| First-Line Gemcitabine Chemotherapy With Our Without Sunitinib In Advanced or Metastatic Pancreatic Cancer | NCT00673504 | Pancreatic Canc... | Gemcitabine + S... Gemcitabine | 18 Years - | Central European Society for Anticancer Drug Research | |
| A Phase 1/2 Trial of SRA737 in Subjects With Advanced Cancer | NCT02797964 | Advanced Solid ... | SRA737 | 18 Years - | Sierra Oncology LLC - a GSK company | |
| A Study to Determine the Safety and Efficacy for the Combination of Durvalumab and Daratumumab in Relapsed and Refractory Multiple Myeloma | NCT02807454 | Multiple Myelom... | Daratumumab Durvalumab Pomalidomide Dexamethasone | 18 Years - | Celgene | |
| Study of SRF617 With AB928 (Etrumadenant) and AB122 (Zimberelimab) in Patients With Metastatic Castration Resistant Prostate Cancer | NCT05177770 | Metastatic Cast... Prostate Cancer | SRF617 etrumadenant zimberelimab | 18 Years - | Coherus Biosciences, Inc. | |
| Safety and Efficacy Therapy of Gemcitabine and Erbitux® to R0 or R1 Resected Pancreatic Cancer | NCT00395252 | Adenocarcinoma | Cetuximab (Erbi... | 18 Years - | Philipps University Marburg Medical Center | |
| Oregovomab Plus Chemotherapy in Neo-adjuvant Setting in Newly Diagnosed Patients With Advanced Epithelial Ovarian Cancer | NCT05605535 | Ovarian Neoplas... Ovarian Cancer Fallopian Tube ... Peritoneal Carc... Ovarian Serous ... | Oregovomab Paclitaxel Carboplatin Placebo | 18 Years - | CanariaBio Inc. | |
| Japanese Phase 2 Study to Evaluate the Efficacy and Safety of Pomalidomide in Subjects With Relapsed and Refractory Multiple Myeloma | NCT02011113 | Multiple Myelom... | Pomalidomide Dexamethasone | 20 Years - | Celgene Corporation | |
| Study of Anti-tumour Effects and Safety of Prolarix™ in Hepatocellular Carcinoma | NCT00746590 | Hepatocellular ... | Prolarix (treta... | 18 Years - | BTG International Inc. | |
| E7050 in Combination With Cetuximab Versus Cetuximab Alone in the Treatment of Platinum-Resistant Squamous Cell Carcinoma of the Head and Neck | NCT01332266 | Platinum-Resist... | E7050 Cetuximab | 18 Years - | Eisai Inc. | |
| Erlotinib Versus Oral Etoposide in Patients With Recurrent or Refractory Pediatric Ependymoma | NCT01032070 | Recurrent or Re... | erlotinib etoposide | 1 Year - 21 Years | Astellas Pharma Inc | |
| A Study With Pembrolizumab in Combination With Dual Anti-HER2 Blockade With Trastuzumab and Pertuzumab in Early Breast Cancer Patients With Molecular HER2-enriched Intrinsic Subtype (Keyriched-1) | NCT03988036 | Breast Cancer | Pembrolizumab Trastuzumab Bio... Pertuzumab | 18 Years - | West German Study Group | |
| An Open-label Study of Encorafenib + Binimetinib in Patients With BRAFV600-mutant Non-small Cell Lung Cancer | NCT03915951 | Non-small Cell ... | encorafenib binimetinib | 18 Years - | Pfizer | |
| Oregovomab Plus Chemotherapy in Neo-adjuvant Setting in Newly Diagnosed Patients With Advanced Epithelial Ovarian Cancer | NCT05605535 | Ovarian Neoplas... Ovarian Cancer Fallopian Tube ... Peritoneal Carc... Ovarian Serous ... | Oregovomab Paclitaxel Carboplatin Placebo | 18 Years - | CanariaBio Inc. | |
| Study of Anti-tumour Effects and Safety of Prolarix™ in Hepatocellular Carcinoma | NCT00746590 | Hepatocellular ... | Prolarix (treta... | 18 Years - | BTG International Inc. | |
| Study of NY-ESO-1 ISCOMATRIX® in Patients With Measurable Stage III or IV Melanoma | NCT00518206 | Melanoma | NY-ESO-1 ISCOMA... Cyclophosphamid... | 18 Years - | Ludwig Institute for Cancer Research |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
